Antibody development using phage display technology

AxioMx technology improvements make phage display antibody development fast, cost-effective, and applicable for broad use in the life sciences.

Phage display antibody discovery is a versatile methodology that was introduced over 30 years ago. Until recently it’s high cost, labor-intensive methods, and long development times made it a tool used almost exclusively for biologics development in large pharmaceutical and biotechnology companies. AxioMx developed a high-throughput phage display antibody development platform making it fast, cost-effective, and applicable for broad use in life science antibody development.

Antibodies developed by phage-display are recombinant and use animal-free methods. The AxioMx platform is based on high-diversity libraries of antibody single chain variable fragments (scFvs) fused to a bacteriophage coat protein (such as Gp3). ScFv antibodies are composed of immunoglobulin heavy and light chain variable domain genes connected by a short peptide linker.

Recombinant antibody technologies, like phage display, present an attractive alternative to traditional antibody generation methods. Because of their speed and flexibility, they are especially useful for isolating antibodies with desired species and protein cross-reactivity characteristics, including binding to specific post-translational modifications, inhibiting receptor-ligand interactions, or recognizing pre-determined antigen domains. In addition, antibodies against toxins and infectious agents can be isolated as no animal immunization is required. Recombinant antibodies are fully renewable with high lot-to-lot consistency and can be genetically engineered to add epitope tags and other sequences.

Custom antibody services

We combine the speed of our phage display methodologies with the versatility of recombinant screening platforms to carefully design antibodies to our customers’ requirements, whether it is a research-grade or diagnostic-purposed antibody.

The phage display scFv recombinant antibody development offers several advantages over traditional monoclonal antibody development. These advantages include

  • Speed: develop custom recombinant monoclonal antibodies in 8 to 10 weeks
  • Consistency: trust in recombinant antibodies that are identical, every batch.
  • Versatility: capitalize on the power of phage display in multiple ways:
    • Develop antibodies to both conventional antigens as well as difficult antigens, like phosphorylated proteins or “non-immunogenic” proteins.
    • Use your antibody in a scFv or an IgG format
    • Optimize antibody frameworks for your applications
  • Specificity: design the desired affinities and specificities into your antibodies
  • All in vitro: develop antibodies without the use of animals

Contact us

If you have any questions about our custom services, please contact us anytime.

Get in touch

Sign up